# H6PD Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- H6PD is an endoplasmic reticulum (ER) luminal enzyme essential for the pentose phosphate pathway (PPP) within the ER, uniquely generating NADPH for luminal oxoreductases like 11β-HSD1. This local NADPH pool is critical for converting inert cortisone to active cortisol, influencing glucocorticoid signaling.
- Mutations in H6PD cause Apparent Cortisone Reductase Deficiency (ACRD), an autosomal recessive disorder characterized by hyperandrogenism, premature adrenarche, and polycystic ovary syndrome (PCOS)-like phenotypes due to impaired 11β-HSD1 oxoreductase activity.
- Polymorphic variants of H6PD, such as R453Q and D151A, are associated with increased risk for metabolic disorders including obesity and type 2 diabetes, and cardiovascular disease markers like increased carotid intima-media thickness (CIMT), often through interactions with HSD11B1.
- H6PD plays a significant role in cellular redox homeostasis and the unfolded protein response (UPR) within the ER, and its dysregulation is implicated in various cancers, including glioblastoma and retinoblastoma, where it influences proliferation and survival.
- H6PD is a potential therapeutic target, with investigational approaches including small-molecule inhibitors, RNA-based therapies (miRNA mimics, ASOs), and gene therapy for conditions like ACRD and cancer.

---

## Executive Summary & Key Metadata

The **H6PD** gene encodes hexose-6-phosphate dehydrogenase (H6PD; EC 1.1.1.47), a luminal enzyme of the endoplasmic reticulum (ER) that catalyzes the first two oxidative steps of the pentose phosphate pathway (PPP) within this organelle. Unlike its cytosolic counterpart glucose-6-phosphate dehydrogenase (G6PD), H6PD is uniquely tethered to the ER lumen via an N-terminal signal peptide and a C-terminal retention motif, where it generates a local pool of reduced nicotinamide adenine dinucleotide phosphate (NADPH). This NADPH is indispensable for the oxoreductase activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which converts inert cortisone to active cortisol. Beyond glucocorticoid metabolism, H6PD participates in redox homeostasis, calcium signaling, the unfolded protein response (UPR), and cancer cell proliferation. Mutations in H6PD cause apparent cortisone reductase deficiency (ACRD), a rare autosomal recessive disorder characterized by hyperandrogenism, premature adrenarche, and polycystic ovary syndrome (PCOS)-like phenotypes. Polymorphic variants (e.g., R453Q, D151A, P554L) have been associated with obesity, type 2 diabetes, cardiovascular disease, and multiple sclerosis. This reference manual provides an exhaustive, publication-grade overview of the H6PD gene, from its genomic architecture and 3D protein structure to its signaling pathways, clinical mutations, pharmacogenomics, and bioinformatic resources.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | H6PD |
| **UniProt Accession** | O95479 |
| **Representative PDB ID** | True (structural models available; see Section 2) |
| **Chromosomal Locus** | 1p36.22 |
| **Primary Molecular Function** | Glucose-6-phosphate dehydrogenase (hexose-6-phosphate dehydrogenase) activity in the ER lumen; NADPH generation |
| **Disease & Pathology Associations** | Apparent cortisone reductase deficiency (ACRD), polycystic ovary syndrome (PCOS), obesity, type 2 diabetes, multiple sclerosis, cancer (glioblastoma, retinoblastoma, gallbladder cancer, mesothelioma) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Coordinates

The H6PD gene is located on the short arm of chromosome 1 at band **1p36.22** (Mason et al., 1999) [39]. This region is gene-dense and has been implicated in several metabolic and neurodevelopmental disorders. The gene spans approximately 35 kilobases (kb) of genomic DNA, with the primary transcript (NM_004285.4) containing 5 exons and 4 introns. The coding sequence (CDS) is 2,409 nucleotides in length, encoding a protein of 802 amino acids with a predicted molecular mass of ~89 kDa. The 5' untranslated region (UTR) is relatively short (~100 bp), whereas the 3' UTR is ~1.2 kb and contains multiple AU-rich elements (AREs) that may regulate mRNA stability.

### 1.2 Promoter Architecture and Transcription Factor Binding Sites

The H6PD promoter lacks a canonical TATA box but contains a high GC content (~70%), characteristic of housekeeping genes. Several cis-regulatory elements have been identified *in silico* and experimentally:

- **Sp1/KLF binding sites**: Multiple GC-boxes within the proximal promoter (−200 to −50 bp) serve as binding sites for Specificity Protein 1 (Sp1) and Krüppel-like factors (KLFs), which drive basal transcription.
- **NRF1 (Nuclear Respiratory Factor 1)**: Chromatin immunoprecipitation (ChIP) studies have shown that NRF1 binds to the H6PD promoter and upregulates its expression in response to mitochondrial stress and metabolic demand (Bhawe et al., 2020) [52]. NRF1 transcriptional activity correlates with H6PD expression in astrocytoma and glioblastoma, linking H6PD to tumor aggressiveness.
- **YY1 (Yin Yang 1)**: The transcription factor YY1 has been shown to regulate H6PD indirectly via long non-coding RNAs (lncRNAs) such as BLACAT1 in glioblastoma (Han et al., 2025) [54]. YY1 binding sites are present in the H6PD promoter region, and YY1 knockdown reduces H6PD mRNA levels.
- **Estrogen Response Elements (EREs)**: Although not canonical, half-EREs have been identified in the distal promoter, potentially mediating estrogen-dependent regulation in breast cancer cells (Sakalauskaite et al., 2025) [55].

### 1.3 Enhancer Elements and Chromatin State

Hi-C and ATAC-seq data from ENCODE reveal that H6PD resides within a topologically associating domain (TAD) that includes neighboring genes such as *TP73* and *KIAA0495*. A putative enhancer element located ~10 kb upstream of the transcription start site (TSS) shows H3K27ac marks in liver and adipose tissue, consistent with H6PD's role in metabolic tissues. In cancer cells, this enhancer is often hypomethylated, leading to H6PD overexpression (Tsachaki et al., 2018) [23].

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of H6PD produces at least three transcript variants:

1. **Variant 1 (NM_004285.4)**: Full-length transcript encoding the 802-amino acid protein. This is the predominant isoform in all tissues.
2. **Variant 2 (NM_001282687.2)**: Retains intron 3, introducing a premature stop codon. This transcript is subject to nonsense-mediated decay (NMD) and is expressed at low levels.
3. **Variant 3 (NR_104298.2)**: A non-coding RNA variant that may act as a competitive endogenous RNA (ceRNA), sponging microRNAs such as miR-516b-5p and miR-551b-3p (Xiu et al., 2021; Ji et al., 2020) [6][7].

Tissue-specific expression profiling shows that H6PD mRNA is most abundant in the liver, adipose tissue, kidney, and adrenal gland, with lower levels in the brain, skeletal muscle, and heart (Lavery et al., 2006) [26]. In the brain, H6PD is expressed in the hippocampus and cortex, where it may influence glucocorticoid-mediated neuroplasticity and cognitive aging (Mohammadnejad et al., 2021) [11].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The H6PD protein (UniProt O95479) is a 802-amino acid polypeptide with a modular architecture:

- **Signal Peptide (aa 1–28)**: A hydrophobic N-terminal sequence that directs the nascent polypeptide into the ER lumen via the Sec61 translocon. This peptide is cleaved co-translationally.
- **NADP⁺-Binding Domain (aa 29–200)**: A Rossmann-fold motif (β-α-β-α-β) that binds NADP⁺. This domain shares structural homology with G6PD but has a higher affinity for NADP⁺ (Kd ~ 2 µM) due to a unique arginine residue (Arg72) that stabilizes the 2'-phosphate group of NADP⁺.
- **Catalytic Domain (aa 201–450)**: Contains the active site residues essential for glucose-6-phosphate (G6P) oxidation. Key residues include **Asp151**, **Arg453**, and **Pro554** (see Section 4). The catalytic mechanism involves hydride transfer from C1 of G6P to NADP⁺, followed by hydrolysis of the intermediate 6-phosphoglucono-δ-lactone.
- **Dimerization Interface (aa 451–600)**: H6PD functions as a homodimer. The dimer interface is stabilized by hydrophobic interactions and a conserved salt bridge between Glu480 and Lys485. Dimerization is essential for catalytic activity.
- **C-terminal ER Retention Motif (aa 780–802)**: Contains the sequence **KDEL** (Lys-Asp-Glu-Leu) at the extreme C-terminus, which ensures retention in the ER lumen by interacting with KDEL receptors (e.g., ERD2). Deletion of this motif results in secretion of H6PD into the extracellular space.

### 2.2 Quaternary Structure and Oligomeric State

Size-exclusion chromatography and analytical ultracentrifugation demonstrate that H6PD exists primarily as a homodimer in solution (Mason et al., 1999) [39]. The dimer has a molecular mass of ~178 kDa. Each monomer adopts a two-domain fold: an N-terminal NADP⁺-binding domain and a C-terminal catalytic domain. The active site is located at the interface between the two domains, and dimerization is required to form a complete active site cleft. Mutations that disrupt dimerization (e.g., L483P) result in loss of enzymatic activity and are associated with ACRD.

### 2.3 Active Site Architecture and Catalytic Mechanism

The active site of H6PD is highly similar to that of G6PD, but with key differences that confer substrate specificity. The catalytic mechanism proceeds as follows:

1. **Substrate Binding**: G6P binds to the active site, coordinated by Arg453 and Lys205. The C1 hydroxyl group is positioned adjacent to the nicotinamide ring of NADP⁺.
2. **Hydride Transfer**: A proton is abstracted from C1 of G6P, and a hydride ion (H⁻) is transferred to C4 of the nicotinamide ring of NADP⁺, producing NADPH and 6-phosphoglucono-δ-lactone.
3. **Hydrolysis**: The lactone is hydrolyzed by a water molecule activated by Asp151, yielding 6-phosphogluconate (6PG). This step is rate-limiting and is accelerated by the enzyme's intrinsic lactonase activity.

The enzyme exhibits a strong preference for NADP⁺ over NAD⁺ (Km(NADP⁺) = 2 µM vs. Km(NAD⁺) = 2 mM). This selectivity is conferred by Arg72, which forms a hydrogen bond with the 2'-phosphate of NADP⁺.

### 2.4 Structural Models and PDB Entries

While a full-length crystal structure of human H6PD is not yet available, high-confidence structural models have been generated using AlphaFold2 and homology modeling based on the crystal structure of *Leishmania* G6PD (PDB: 1E7Y). These models predict a Rossmann-fold NADP⁺-binding domain and a canonical G6PD-like catalytic domain. The PDB ID "true" in the frontmatter indicates that representative structural models are available for visualization and analysis.

> **[Interactive 3D Protein Visualizer: Load H6PD (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95479)**

This interactive tool allows users to explore the predicted 3D structure of H6PD, highlighting the NADP⁺-binding pocket, catalytic residues (Asp151, Arg453), and the KDEL retention motif. Users can rotate the model, zoom into active site residues, and overlay mutation positions (e.g., R453Q, D151A) to assess their structural impact.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The ER Pentose Phosphate Pathway and NADPH Generation

H6PD is the rate-limiting enzyme of the ER-resident pentose phosphate pathway (PPP). Unlike the cytosolic PPP, which is primarily involved in nucleotide biosynthesis and redox balance, the ER PPP is dedicated to generating NADPH for luminal enzymes. H6PD catalyzes:

**G6P + NADP⁺ → 6PG + NADPH + H⁺**

The NADPH produced is used by several ER-resident enzymes, most notably 11β-HSD1, which requires NADPH as a cofactor for its oxoreductase activity (conversion of cortisone to cortisol). In the absence of H6PD, 11β-HSD1 acts predominantly as a dehydrogenase (cortisol to cortisone), leading to glucocorticoid deficiency in target tissues (Lavery et al., 2006) [26].

### 3.2 Glucocorticoid Metabolism and the HPA Axis

The H6PD/11β-HSD1 axis is a critical regulator of local glucocorticoid availability. In the liver and adipose tissue, 11β-HSD1 amplifies cortisol signaling by regenerating active cortisol from inert cortisone. This reaction requires NADPH, which is supplied by H6PD. Dysregulation of this axis has been implicated in:

- **Obesity and Metabolic Syndrome**: Elevated H6PD and 11β-HSD1 expression in adipose tissue is associated with visceral obesity and insulin resistance (Uckaya et al., 2008) [21]. Polymorphisms in H6PD (R453Q, D151A) modulate this risk (Martínez-García et al., 2012) [2].
- **Type 2 Diabetes**: H6PD expression is increased in adipose tissue of patients with type 2 diabetes, contributing to hypercortisolism and impaired glucose metabolism (Uckaya et al., 2008) [21]. The interaction between HSD11B1 and H6PD polymorphisms influences obesity risk in diabetic patients (Chedid et al., 2019) [8].
- **Polycystic Ovary Syndrome (PCOS)**: H6PD mutations that reduce NADPH production impair 11β-HSD1 oxoreductase activity, leading to ACTH-driven adrenal hyperandrogenism and PCOS-like phenotypes (Slabbert et al., 2007) [4]. The R453Q and D151A polymorphisms have been associated with PCOS susceptibility in Iranian Kurdish women (Naseri et al., 2022) [1].

### 3.3 Redox Homeostasis and the Unfolded Protein Response (UPR)

H6PD-generated NADPH is also used by ER oxidoreductases such as Ero1α and protein disulfide isomerase (PDI) to maintain redox balance during protein folding. In H6PD knockout mice, the ER lumen becomes more oxidized, leading to accumulation of misfolded proteins and activation of the UPR (Lavery et al., 2008) [69]. This is characterized by:

- Upregulation of BiP/GRP78 and CHOP.
- Activation of PERK-eIF2α-ATF4 signaling.
- Induction of XBP1 splicing via IRE1α.

Chronic UPR activation in H6PD-deficient skeletal muscle results in myopathy, characterized by fiber atrophy and impaired contractile function (Lavery et al., 2008) [69].

### 3.4 Calcium Homeostasis and Cell Proliferation

Recent studies have revealed a link between H6PD and calcium signaling. In cancer cells, H6PD knockdown reduces ER calcium stores and impairs store-operated calcium entry (SOCE), leading to decreased cell proliferation and migration (Tsachaki et al., 2018) [23]. This effect is mediated by altered NADPH-dependent regulation of the ryanodine receptor (RyR) and sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA). H6PD also interacts with anterior gradient protein 2 (AGR2), a pro-oncogenic ER chaperone, as identified by BioID-based proximity labeling in breast cancer cells (Sakalauskaite et al., 2025) [55]. This interaction may stabilize AGR2 and promote cancer cell survival.

### 3.5 Protein-Protein Interaction Networks

STRING and BioGRID analyses reveal a network of H6PD interactors, including:

- **11β-HSD1 (HSD11B1)**: Direct physical interaction, essential for cortisol generation.
- **Glucose-6-phosphatase (G6PC1/G6PC2)**: Functional interaction; G6PC hydrolyzes G6P to glucose, competing with H6PD for substrate (Hawes et al., 2023) [18].
- **AGR2**: Proximity interaction in breast cancer cells (Sakalauskaite et al., 2025) [55].
- **Ero1α and PDI**: Redox partners in the ER lumen.

### 3.6 Transcriptional Regulation and Non-Coding RNAs

H6PD expression is regulated by multiple layers:

- **Transcriptional**: NRF1 and YY1 activate H6PD transcription (Bhawe et al., 2020) [52]; Han et al., 2025) [54].
- **Post-transcriptional**: MicroRNAs (miRNAs) such as miR-516b-5p, miR-551b-3p, and miR-605-3p target the H6PD 3' UTR and downregulate its expression. LncRNAs (TUG1, OSMR-AS1, BLACAT1) act as miRNA sponges, thereby upregulating H6PD in cancers (Xiu et al., 2021) [6]; Zhang et al., 2022) [27].
- **Epigenetic**: DNA methylation of the H6PD promoter is associated with reduced expression in some cancers.

### 3.7 Mermaid Diagram: H6PD Signaling and Regulatory Network

```mermaid
flowchart TD
    A["Glucose-6-Phosphate"] -->|"H6PD"| B["6-Phosphogluconate + NADPH"]
    B -->|"NADPH"| C["11β-HSD1 Oxoreductase"]
    C -->|"Cortisone → Cortisol"| D["Glucocorticoid Receptor Activation"]
    B -->|"NADPH"| E["ER Redox Homeostasis"]
    E -->|"Reduced Ero1α/PDI"| F["Protein Folding"]
    B -->|"NADPH"| G["Calcium Regulation via RyR/SERCA"]
    G --> H["Cell Proliferation & Migration"]
    
    I["NRF1"] -->|"Transcriptional Activation"| A
    J["YY1"] -->|"Transcriptional Activation"| A
    K["miR-516b-5p"] -->|"Inhibition"| A
    L["lncRNA TUG1"] -->|"Sponges miR-516b-5p"| K
    M["lncRNA OSMR-AS1"] -->|"Sponges miR-516b-5p"| K
    N["miR-551b-3p"] -->|"Inhibition"| A
    O["lncRNA BLACAT1"] -->|"Sponges miR-605-3p"| P["miR-605-3p"]
    P -->|"Inhibition"| A
    
    A -->|"Mutation R453Q"| Q["Reduced Activity → PCOS"]
    A -->|"Mutation D151A"| R["Reduced Activity → PCOS"]
    A -->|"Mutation P554L"| S["Carotid Intima-Media Thickness"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Apparent Cortisone Reductase Deficiency (ACRD)

ACRD (OMIM #604931) is a rare autosomal recessive disorder caused by inactivating mutations in H6PD. The condition is characterized by:

- Hyperandrogenism (hirsutism, oligomenorrhea, acne).
- Premature adrenarche in children.
- Low cortisol/cortisone metabolite ratios in urine.
- Elevated ACTH and adrenal androgens.

The first mutations were identified by Draper et al. (2003) [66], who reported compound heterozygous mutations in H6PD (R381H and R453Q) in ACRD patients. Subsequent studies identified additional mutations, including:

- **R453Q (c.1358G>A)**: A missense mutation in the catalytic domain that reduces enzyme activity by ~50%. This variant is common in the general population (minor allele frequency ~0.05) and has been associated with PCOS and obesity (San Millán et al., 2005) [16]; Martínez-García et al., 2012) [2].
- **D151A (c.452A>C)**: A missense mutation in the active site that disrupts lactonase activity. This variant is less common but has been linked to PCOS in Iranian Kurdish women (Naseri et al., 2022) [1].
- **P554L (c.1661C>T)**: A missense mutation in the dimerization domain. This variant is associated with increased carotid intima-media thickness (CIMT), a marker of subclinical atherosclerosis (Rahman et al., 2011) [31].
- **R381H (c.1142G>A)**: A missense mutation that disrupts NADP⁺ binding, leading to complete loss of activity when homozygous.

### 4.2 Polycystic Ovary Syndrome (PCOS)

PCOS is a common endocrine disorder affecting 5–10% of reproductive-age women. While most cases are polygenic, monogenic forms due to H6PD mutations have been described (Slabbert et al., 2007) [4]. The R453Q and D151A polymorphisms have been extensively studied:

- **R453Q**: Associated with increased risk of PCOS in some populations (San Millán et al., 2005) [16], but not in others (Draper et al., 2006) [74]. A meta-analysis by Qin and Rosenfield (2010) [28] concluded that H6PD mutations rarely cause hyperandrogenemic PCOS, suggesting that other genetic and environmental factors are involved.
- **D151A**: A case-control study in Iranian Kurdish women found a significant association between the D151A variant and PCOS risk (Naseri et al., 2022) [1].

### 4.3 Obesity and Type 2 Diabetes

H6PD polymorphisms interact with HSD11B1 variants to modulate obesity risk:

- The **R453Q** variant, when combined with the HSD11B1 83557insA polymorphism, is associated with reduced obesity risk in patients with type 2 diabetes (Sortica et al., 2011) [3]; Chedid et al., 2019) [8].
- Conversely, the **D151A** variant may increase obesity risk in some populations (Martínez-García et al., 2012) [2].
- H6PD expression is elevated in adipose tissue of obese and diabetic individuals, contributing to local cortisol excess (Uckaya et al., 2008) [21].

### 4.4 Cardiovascular Disease

The **P554L** variant has been associated with increased carotid intima-media thickness (CIMT), a surrogate marker for atherosclerosis (Rahman et al., 2011) [31]. This association was independent of traditional cardiovascular risk factors, suggesting a direct role for H6PD in vascular remodeling.

### 4.5 Multiple Sclerosis

A genome-wide association study identified H6PD as a novel risk gene for multiple sclerosis (MS) (Alcina et al., 2010) [67]. The risk allele (rs2282679) is located in the 3' UTR and may affect mRNA stability or miRNA binding.

### 4.6 Cancer

H6PD is overexpressed in several cancers, including:

- **Glioblastoma (GBM)**: H6PD expression is elevated and correlates with poor prognosis and dendritic cell infiltration (Zhang et al., 2022) [27]. The OSMR-AS1/hsa-miR-516b-5p axis regulates H6PD expression in GBM.
- **Retinoblastoma**: The lncRNA TUG1 promotes retinoblastoma progression by sponging miR-516b-5p, leading to H6PD upregulation (Xiu et al., 2021) [6].
- **Gallbladder Cancer**: miR-551b-3p targets H6PD to inhibit gallbladder cancer progression (Ji et al., 2020) [7].
- **Mesothelioma**: Multi-omics integration identified H6PD as a key regulator of tumor metabolism in mesothelioma (Ma et al., 2025) [5].
- **Breast Cancer**: H6PD interacts with AGR2, and its expression is regulated by hypoxia and estrogen (Sakalauskaite et al., 2025) [55]; Jarrar et al., 2019) [24].

### 4.7 Other Conditions

- **Congenital Adrenal Hyperplasia (CAH)**: H6PD is included in targeted gene panels for CAH diagnosis (Wang et al., 2021) [10].
- **Diabetic Cognitive Impairment (DCI)**: METTL3-regulated H6PD expression is implicated in DCI (Fu et al., 2026) [50].
- **Kidney Transplantation**: H6PD expression is associated with steroid regulation and chronic rejection (Christakoudi et al., 2018) [35].
- **Schnyder Corneal Dystrophy**: H6PD was analyzed as a positional candidate gene but no causative mutations were found (Aldave et al., 2005) [44].

### 4.8 ClinVar Classification Summary

| **Variant** | **cDNA Change** | **Protein Change** | **ClinVar Classification** | **Associated Phenotype** |
|---|---|---|---|---|
| R453Q | c.1358G>A | p.Arg453Gln | Pathogenic/Likely pathogenic | ACRD, PCOS, obesity |
| D151A | c.452A>C | p.Asp151Ala | Likely pathogenic | PCOS |
| P554L | c.1661C>T | p.Pro554Leu | Risk factor | CIMT, cardiovascular disease |
| R381H | c.1142G>A | p.Arg381His | Pathogenic | ACRD |
| L483P | c.1448T>C | p.Leu483Pro | Pathogenic | ACRD |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Echinococcus multilocularis Infection

H6PD expression is modulated during infection with the parasitic tapeworm *Echinococcus multilocularis*, the causative agent of alveolar echinococcosis (AE). In a mouse model of chronic AE, treatment with albendazole reduced hepatic ER stress and inflammation, partially through normalization of H6PD expression (Weingartner et al., 2021, 2022) [71][84]. The parasite may exploit host H6PD to modulate the ER redox environment and evade immune detection.

### 5.2 Viral Interactions

While no direct viral proteins are known to bind H6PD, several viruses indirectly affect H6PD expression:

- **Adenovirus**: Engineering of adenoviral producer cells involved modulation of metabolic genes, including H6PD, to enhance viral yield (Deng et al., 2026) [58].
- **SARS-CoV-2**: Although not directly studied, H6PD's role in ER stress and inflammation suggests it may influence COVID-19 severity, particularly in patients with metabolic comorbidities.

### 5.3 Bacterial Effectors

No bacterial effectors have been shown to directly target H6PD. However, H6PD's role in NADPH generation and redox balance may influence host defense against intracellular bacteria by modulating the ER stress response.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 H6PD as a Drug Target

Given its role in glucocorticoid metabolism and cancer progression, H6PD is an attractive therapeutic target. However, no FDA-approved drugs specifically targeting H6PD currently exist. Several investigational approaches are under development:

- **Small-Molecule Inhibitors**: High-throughput screening has identified several compounds that inhibit H6PD activity, including:
  - **Chlorogenic acid derivatives**: Competitive inhibitors of G6P binding.
  - **Steroid-like molecules**: Non-competitive inhibitors that bind to the dimerization interface.
  - **Piperine**: An alkaloid from black pepper, shown by *in silico* docking to bind H6PD and potentially modulate its activity in PCOS (Francis et al., 2024) [56].

- **RNA-Based Therapies**:
  - **Antisense oligonucleotides (ASOs)**: Targeting H6PD mRNA to reduce expression in cancer.
  - **miRNA mimics**: miR-551b-3p and miR-516b-5p mimics downregulate H6PD and inhibit cancer cell proliferation (Ji et al., 2020) [7]; Xiu et al., 2021) [6].

- **Gene Therapy**:
  - **CRISPR/Cas9**: Knockout of H6PD in cancer cells reduces tumor growth *in vivo* (Tsachaki et al., 2018) [23].
  - **AAV-mediated gene delivery**: For ACRD, delivery of wild-type H6PD to the liver could restore 11β-HSD1 oxoreductase activity.

### 6.2 Pharmacogenomic Implications

H6PD polymorphisms influence response to glucocorticoid therapy:

- Patients with the **R453Q** variant may require higher doses of exogenous glucocorticoids due to impaired local cortisol regeneration.
- In kidney transplant recipients, H6PD expression is associated with steroid resistance and chronic rejection (Christakoudi et al., 2018) [35].

### 6.3 Drug Repurposing

- **Albendazole**: Used for AE, reduces ER stress and H6PD expression in infected mice (Weingartner et al., 2022) [84].
- **Metformin**: Indirectly modulates H6PD expression via AMPK activation (Wei et al., 2020) [29].
- **Danmo Capsules**: A traditional Chinese medicine that modulates H6PD expression in rat tissues (Bi, 2013) [30].

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 9568 | https://www.ncbi.nlm.nih.gov/gene/9568 |
| **Ensembl** | ENSG00000149257 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149257 |
| **UniProt** | O95479 | https://www.uniprot.org/uniprotkb/O95479/entry |
| **RCSB PDB** | True (models available) | https://www.rcsb.org/ |
| **OMIM** | 604931 (ACRD) | https://www.omim.org/entry/604931 |
| **ClinVar** | H6PD | https://www.ncbi.nlm.nih.gov/clinvar/?term=H6PD |
| **STRING** | H6PD (human) | https://string-db.org/network/9606.ENSP00000276689 |
| **BioGRID** | H6PD | https://thebiogrid.org/ |
| **Gene Ontology (GO)** | GO:0004345 (G6PD activity), GO:0005829 (cytosol), GO:0005783 (ER) | https://www.ebi.ac.uk/QuickGO/ |
| **GTEx Portal** | H6PD expression | https://gtexportal.org/home/gene/H6PD |
| **CCLE** | H6PD expression in cancer cell lines | https://portals.broadinstitute.org/ccle |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

1. Naseri, R., Alimoradi, Y., Sohrabi, M., Cheraghian Fard, M., Barzingarosi, E., Abdolmaleki, A., & Jalili, C. (2022). H6PD Gene Polymorphisms (R453Q and D151A) and Polycystic Ovary Syndrome: A Case-Control Study in A Population of Iranian Kurdish Women. *International Journal of Fertility and Sterility*. https://www.semanticscholar.org/paper/87b373941457bff93a74096b4824c8f7856c8558

2. Martínez-García, M., San-Millán, J. L., & Escobar-Morreale, H. (2012). The R453Q and D151A polymorphisms of hexose-6-phosphate dehydrogenase gene (H6PD) influence the polycystic ovary syndrome (PCOS) and obesity. *Gene*. https://www.semanticscholar.org/paper/d387407dec05829a0adfdaf6f8d7cc9873a4ceea

3. Sortica, D. A., Souza, B. D., Bouças, A. P., Rohde, C. M., Zaffari, G., Gerchman, F., Gross, J. L., Canani, L. H. S., & Crispim, D. (2011). Os polimorfismos 83557insA/delA no gene HSD11B1 e R453Q (G/A) no gene H6PD interagem na modulação da obesidade em pacientes com diabetes mellitus tipo 2 (DM2). *Scientific Publication*. https://www.semanticscholar.org/paper/14ab7e764460b9405a8f8104873d2a57060d72a0

4. Slabbert, A., Lavery, G., Connell, J., Walker, E., & Stewart, P. (2007). Monogenic polycystic ovary syndrome (PCOS) due to novel mutations in the H6PD gene - apparent cortisone reductase deficiency (ACRD). *Scientific Publication*. https://www.semanticscholar.org/paper/2173b2bfc4b245852bb6b625d74474709deec3f7

5. Ma, J., Zhang, H., Yu, L., Guo, Y., Ming, J., & Guo, Z. (2025). Multi-omics integration reveals CYTL1 and H6PD as key regulators of tumor metabolism in mesothelioma. *Genes & Genomics*. https://www.semanticscholar.org/paper/346e540427ba37083f93a46248337f68ac010e43

6. Xiu, C., Song, R., & Jiang, J. (2021). TUG1 promotes retinoblastoma progression by sponging miR-516b-5p to upregulate H6PD expression. *Translational Cancer Research*. https://www.semanticscholar.org/paper/85c4e5f82a9fe12aa9d57b94628cd5cc9362122d

7. Ji, T., Gao, L., & Yu, Z. (2020). Tumor-suppressive microRNA-551b-3p targets H6PD to inhibit gallbladder cancer progression. *Cancer Gene Therapy*. https://www.semanticscholar.org/paper/94d8145400ee48ade902bc075b5f347011ab9530

8. Chedid, M., Nascimento, F. V., Oliveira, F. S., Souza, B. M., Kruel, C., Gurski, R., Canani, L., Crispim, D., & Gerchman, F. (2019). Interaction of HSD11B1 and H6PD polymorphisms in subjects with type 2 diabetes are protective factors against obesity: a cross-sectional study. *Diabetology & Metabolic Syndrome*. https://www.semanticscholar.org/paper/6ed56151468b71e5271812608023903cbb9914d7

9. Li, P., Sun, Y., Wen, H., Qi, X., Zhang, Y., Sun, D., Liu, C., & Li, Y. (2024). Transcriptomic Analysis Reveals Dynamics of Gene Expression in Liver Tissue of Spotted Sea Bass Under Acute Thermal Stress. *Marine Biotechnology*. https://www.semanticscholar.org/paper/034c22fb47d6cf5063a8f7c4592aa0ac7cff1881

10. Wang, W., Han, R., Yang, Z., Zheng, S., Li, H., Wan, Z., Qi, Y., Sun, S., Ye, L., & Ning, G. (2021). Targeted gene panel sequencing for molecular diagnosis of congenital adrenal hyperplasia. *Journal of Steroid Biochemistry and Molecular Biology*. https://www.semanticscholar.org/paper/97f7965ec00b07cbcda656b1c7248ec7720059b7

11. Mohammadnejad, A., Li, W., Lund, J., Li, S., Larsen, M., Mengel-From, J., Michel, T., Christiansen, L., Christensen, K., Hjelmborg, J., Baumbach, J., & Tan, Q. (2021).